| #<\/th> | ID<\/th> | Presenter<\/th> | A<\/th> | B<\/th> | C<\/th> | Session<\/th> | Title<\/th><\/tr> |
|---|
| 1<\/td> | 43595_78<\/td> | Meyad Alkarni<\/td> | D1P1<\/td> | 01<\/td> | 01<\/td> | BASIC SCIENCE 1<\/td> | Early Insights into Immunological and Transcriptomic Signatures Related to Radiological Severity in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)<\/td><\/tr> |
| 2<\/td> | 44087_445<\/td> | Braune Anna Z.<\/td> | D1P1<\/td> | 01<\/td> | 02<\/td> | BASIC SCIENCE 1<\/td> | Feasibility and Safety of Outpatient Parenteral Antibiotic Therapy (OPAT) in Adults with Cystic Fibrosis, Bronchiectasis, Primary Ciliary Dyskinesia and NTM Pulmonary Disease \u2013 a Single-Center, Retrospective Cohort Study<\/td><\/tr> |
| 3<\/td> | 43986_344<\/td> | Crystal Bourke<\/td> | D1P1<\/td> | 01<\/td> | 03<\/td> | BASIC SCIENCE 1<\/td> | Mucus is hyperconcentrated in children with bronchiectasis compared to healthy children<\/td><\/tr> |
| 4<\/td> | 43831_204<\/td> | Erin Cant<\/td> | D1P1<\/td> | 01<\/td> | 04<\/td> | BASIC SCIENCE 1<\/td> | Mucociliary clearance in the lower airways in bronchiectasis: data from the BRILLIANT study<\/td><\/tr> |
| 5<\/td> | 43871_242<\/td> | Raphael Ewen<\/td> | D1P1<\/td> | 01<\/td> | 05<\/td> | BASIC SCIENCE 1<\/td> | Evaluation of Serum Azurocidin (AZU-1) as a potential biomarker of disease activity and predictor of exacerbations in adults with bronchiectasis: Data from the German Bronchiectasis Registry PROGNOSIS<\/td><\/tr> |
| 6<\/td> | 44069_428<\/td> | Paola Faverio<\/td> | D1P1<\/td> | 01<\/td> | 06<\/td> | BASIC SCIENCE 1<\/td> | Impact of geographic and climatic variables and environmental athmospheric pollutants on pulmonary NTM infections: an Italian nationwide case-control study<\/td><\/tr> |
| 7<\/td> | 43708_96<\/td> | Laura Fawcett<\/td> | D1P1<\/td> | 01<\/td> | 07<\/td> | BASIC SCIENCE 1<\/td> | STAKEHOLDER ACCEPTABILITY OF PATIENT-DERIVED ORGANOIDS FOR PERSONALISED MEDICINE IN CYSTIC FIBROSIS<\/td><\/tr> |
| 8<\/td> | 43875_245<\/td> | Hye Young Hong<\/td> | D1P1<\/td> | 01<\/td> | 08<\/td> | BASIC SCIENCE 1<\/td> | Body mass index trajectory and the risk of bronchiectasis exacerbation: An analysis of the KMBARC cohort<\/td><\/tr> |
| 9<\/td> | 44191_491<\/td> | ATIQUR RAHMAN KHAN<\/td> | D1P1<\/td> | 01<\/td> | 09<\/td> | BASIC SCIENCE 1<\/td> | Modern Approaches to Paediatric Bronchiectasis: From Early Recognition to Precision Therapy<\/td><\/tr> |
| 10<\/td> | 43398_51<\/td> | Linda Kunz<\/td> | D1P1<\/td> | 01<\/td> | 10<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | Bronchoalveolar lavage as a diagnostic tool for assessing disease activity in bronchiectasis<\/td><\/tr> |
| 11<\/td> | 43746_121<\/td> | Melissa McDaniel<\/td> | D1P1<\/td> | 01<\/td> | 11<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | A secreted factor of Pseudomonas aeruginosa rapidly kills non-tuberculous mycobacteria in biofilms in vitro<\/td><\/tr> |
| 12<\/td> | 44197_496<\/td> | Sonja Momchilovikj<\/td> | D1P1<\/td> | 01<\/td> | 12<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | Clinical and Microbiological Characteristics of Hospitalized Patients with Bronchiectasis \u2013 A One-Year Retrospective Analysis in North Macedonia<\/td><\/tr> |
| 13<\/td> | 43399_52<\/td> | Ilgar Mustafayev<\/td> | D1P1<\/td> | 01<\/td> | 13<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | Relationship between the Severity of the Clinical Course of primary bronchiectasis (BE) and Family and Genetic History<\/td><\/tr> |
| 14<\/td> | 43833_206<\/td> | Narin\u00e9 Baririan<\/td> | D1P1<\/td> | 02<\/td> | 01<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | Florensocatib (dipeptidyl peptidase-1 inhibitor) Phase I study in healthy Caucasian subjects<\/td><\/tr> |
| 15<\/td> | 43731_113<\/td> | Joe Brew<\/td> | D1P1<\/td> | 02<\/td> | 02<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | Validation of a Privacy-Preserving Cough Monitoring Smartwatch Against Human-Annotated Ground Truth in Adults with Chronic Cough: A Decentralized, Real-World Study<\/td><\/tr> |
| 16<\/td> | 43789_169<\/td> | Zhongbo Chen<\/td> | D1P1<\/td> | 02<\/td> | 03<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | Comparison of High-Flow Humidified Nasal Oxygen Therapy and Non-invasive Ventilation as an Initial Ventilation Strategy in Acute Exacerbation of Bronchiectasis with Mild to Moderate Hypercapnia:Study Protocol<\/td><\/tr> |
| 17<\/td> | 43860_232<\/td> | Zhongbo Chen<\/td> | D1P1<\/td> | 02<\/td> | 04<\/td> | BASIC SCIENCE and REGISTRIES SESSION<\/td> | Efficacy and Safety of High-Flow Nasal Cannula Oxygen Therapy versus Conventional Oxygen Therapy in Patients with Acute Exacerbation of Bronchiectasis: Study Protocol for a Multicenter, Randomized Controlled Trial<\/td><\/tr> |
| 18<\/td> | 43404_54<\/td> | James D. Chalmers<\/td> | D1P1<\/td> | 02<\/td> | 05<\/td> | REGISTRIES & TRAILS 1<\/td> | Florensocatib, an inhibitor of dipeptidyl peptidase-1, for the treatment of non-cystic fibrosis bronchiectasis: Rationale and Design of the FABLE Phase III trial<\/td><\/tr> |
| 19<\/td> | 43779_160<\/td> | James D. Chalmers<\/td> | D1P1<\/td> | 02<\/td> | 06<\/td> | REGISTRIES & TRAILS 1<\/td> | Subgroup analysis: AIRLEAF\u00ae Phase II study of a dipeptidyl peptidase 1 (DPP1, or CatC) inhibitor, verducatib, in adults with non\u2013cystic fibrosis bronchiectasis<\/td><\/tr> |
| 20<\/td> | 43888_255<\/td> | Raya Cohen<\/td> | D1P1<\/td> | 02<\/td> | 07<\/td> | REGISTRIES & TRAILS 1<\/td> | Long term outcomes of patients with Nocardia isolation in respiratory secretions \u2013 a retrospective cohort study<\/td><\/tr> |
| 21<\/td> | 43899_265<\/td> | Meg Crisafulli<\/td> | D1P1<\/td> | 02<\/td> | 08<\/td> | REGISTRIES & TRAILS 1<\/td> | The Australian Bronchiectasis Registry: Demographic and Aetiological Characteristics of a National Adult and Paediatric Cohort<\/td><\/tr> |
| 22<\/td> | 43933_292<\/td> | Fabiana Cusati<\/td> | D1P1<\/td> | 02<\/td> | 09<\/td> | REGISTRIES & TRAILS 1<\/td> | Effectiveness of inhaled colistin in bronchiectasis: a real-world analysis from the REPAIR registry.<\/td><\/tr> |
| 23<\/td> | 43828_201<\/td> | Patrick A. Flume<\/td> | D1P1<\/td> | 02<\/td> | 10<\/td> | REGISTRIES & TRAILS 1<\/td> | Clinical outcome burden in people with bronchiectasis by baseline pulmonary exacerbation frequency: A real-world data analysis<\/td><\/tr> |
| 24<\/td> | 44057_417<\/td> | Lingyun Gao<\/td> | D1P1<\/td> | 02<\/td> | 11<\/td> | REGISTRIES & TRAILS 1<\/td> | Development and Validation of an Inflammation-Nutrition-CT Integrated Risk Score (INCT-RS) for Predicting Progression from Asymptomatic Radiological Bronchiectasis to Clinical Bronchiectasis<\/td><\/tr> |
| 25<\/td> | 44067_426<\/td> | Rebecca Hull<\/td> | D1P1<\/td> | 02<\/td> | 12<\/td> | REGISTRIES & TRAILS 1<\/td> | Inhaled Aztreonam lysine to treat chronic Gram-negative infections in patients with bronchiectasis: results from the VITAL-BE trial<\/td><\/tr> |
| 26<\/td> | 44071_430<\/td> | Merete B Long<\/td> | D1P1<\/td> | 02<\/td> | 13<\/td> | REGISTRIES & TRAILS 1<\/td> | Alpha-1 antitrypsin augmentation in people with bronchiectasis and neutrophilic airway inflammation: results from the proof-of-concept BATMAN trial<\/td><\/tr> |
| 27<\/td> | 43921_281<\/td> | Pontus Mertsch<\/td> | D1P1<\/td> | 02<\/td> | 14<\/td> | REGISTRIES & TRAILS 1<\/td> | InhalEd ColiFin\u00ae in adult bRonchiectasis pAtients with new asymptomatic PseuDomonas aerugInosa infeCtion\u2013 an open-lAbel, proof of concepT- randomizEd controlled trial (ERADICATE)<\/td><\/tr> |
| 28<\/td> | 44193_493<\/td> | Sayina Abudukeyoumu<\/td> | D1P1<\/td> | 03<\/td> | 01<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | Development and validation of a prognostic score for ABPA relapse: a retrospective-prospective cohort study<\/td><\/tr> |
| 29<\/td> | 43826_199<\/td> | Ke Li Chow<\/td> | D1P1<\/td> | 03<\/td> | 02<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | Identification of novel autoantibodies to unlock targeted treatments and diagnostics in idiopathic non-cystic fibrosis bronchiectasis<\/td><\/tr> |
| 30<\/td> | 43840_216<\/td> | Carlos Gallego Mol<\/td> | D1P1<\/td> | 03<\/td> | 03<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | The Progressive Burden of Bronchiectasis: Comparing Quality of Life Outcomes Between Hospitalised and Non-Hospitalised Patients in BronchUK<\/td><\/tr> |
| 31<\/td> | 44077_436<\/td> | Jiahui He<\/td> | D1P1<\/td> | 03<\/td> | 04<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | Serum Azurocidin-1 in bronchiectasis: a pilot study exploring clinical associations<\/td><\/tr> |
| 32<\/td> | 43798_178<\/td> | Raksha Jain<\/td> | D1P1<\/td> | 03<\/td> | 05<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | Sex-specific and estrogen modulation of neutrophil function in bronchiectasis with and without cystic fibrosis<\/td><\/tr> |
| 33<\/td> | 43753_128<\/td> | Chrysavgi Kosti<\/td> | D1P1<\/td> | 03<\/td> | 06<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | Phenotyping eosinophilic inflammation spectrum in bronchiectasis: data from a single centre in Greece<\/td><\/tr> |
| 34<\/td> | 43901_267<\/td> | Chaabouni Malek<\/td> | D1P1<\/td> | 03<\/td> | 07<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | Case Report: Broncholithiasis in a Patient with Bronchiectasis and COPD<\/td><\/tr> |
| 35<\/td> | 43825_198<\/td> | Keshav Mangalick<\/td> | D1P1<\/td> | 03<\/td> | 08<\/td> | Comorbidities, Immunology & Inflammation 1<\/td> | Cachexia is associated with Distinct Microbiome Signatures in the Lower Airway of Patients with Bronchiectasis<\/td><\/tr> |
| 36<\/td> | 43643_86<\/td> | Doreen Addrizzo-Harris<\/td> | D1P2<\/td> | 04<\/td> | 01<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Efficacy and Safety of Brensocatib in Patients of Asian Race with Non-cystic Fibrosis Bronchiectasis (NCFB): A Subgroup Analysis of the ASPEN Trial<\/td><\/tr> |
| 37<\/td> | 44083_441<\/td> | Doha BENCHAJI<\/td> | D1P2<\/td> | 04<\/td> | 02<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Clinical and Radiological Profile of Cystic Fibrosis Associated Bronchiectasis: A Descriptive Study of 19 Patients in Morocco<\/td><\/tr> |
| 38<\/td> | 43897_263<\/td> | Judy M Bradley<\/td> | D1P2<\/td> | 04<\/td> | 03<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Unsupervised home spirometry versus supervised clinic spirometry: Analysis of longitudinal participant-level data from the CLEAR trial in patients with bronchiectasis<\/td><\/tr> |
| 39<\/td> | 43771_145<\/td> | Amanda Brunton<\/td> | D1P2<\/td> | 04<\/td> | 04<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Association of Inhaled Corticosteroid Use and Clinical Outcomes in Patients with Bronchiectasis<\/td><\/tr> |
| 40<\/td> | 43190_33<\/td> | Isaac Cohen<\/td> | D1P2<\/td> | 04<\/td> | 05<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | MCCSA2 a Combination of the b- agonist Formoterol and the Cholinergic Agonist Methacholine Induce Synergistic Activation of Mucociliary Clearance in a CFTR Independent Manner<\/td><\/tr> |
| 41<\/td> | 43808_185<\/td> | Annemarie T. Engel<\/td> | D1P2<\/td> | 04<\/td> | 06<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Pediatric simulations of verducatib (BI 1291583) in adolescents to support Phase III dose selection<\/td><\/tr> |
| 42<\/td> | 44076_435<\/td> | Ashleigh Foubister<\/td> | D1P2<\/td> | 04<\/td> | 07<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Impaired B-cell responses to P. aeruginosa and their impact on antibody production in bronchiectasis; a substudy in the EMBARC-BRIDGE cohort<\/td><\/tr> |
| 43<\/td> | 44061_421<\/td> | Rui Jiang<\/td> | D1P2<\/td> | 04<\/td> | 08<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Plasma Proteomic Signatures for Incident Bronchiectasis: Causal Validation, Severity Stratification, and Predictive Modeling<\/td><\/tr> |
| 44<\/td> | 43772_146<\/td> | Joseph Kibbler<\/td> | D1P2<\/td> | 04<\/td> | 09<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | BRACE - a multicentre UK audit of multidisciplinary bronchiectasis care<\/td><\/tr> |
| 45<\/td> | 43754_129<\/td> | Jinliang Kong<\/td> | D1P2<\/td> | 04<\/td> | 10<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Navigating Therapeutic Dilemmas: Management of Pseudomonas aeruginosa Pneumonia in a Patient with Severe Immune Thrombocytopenia and Underlying Bronchiectasis\u2014A Case Report<\/td><\/tr> |
| 46<\/td> | 44195_495<\/td> | Mariana Lima<\/td> | D1P2<\/td> | 04<\/td> | 11<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | A rare X-linked cause of bronchiectasis<\/td><\/tr> |
| 47<\/td> | 43546_77<\/td> | Jia hui He<\/td> | D1P2<\/td> | 04<\/td> | 12<\/td> | Cystic Fibrosis and Bronchiectasis 1<\/td> | Platelet count, clinical outcomes, and antibiotic and anti-inflammatory treatment in adults with bronchiectasis<\/td><\/tr> |
| 48<\/td> | 44058_418<\/td> | Rachel Anderson<\/td> | D1P2<\/td> | 05<\/td> | 01<\/td> | Management & Organization of clinical service<\/td> | Optimising paediatric to adult transition clinics for patients with Non-Cystic Fibrosis Bronchiectasis: A thematic analysis of data collected from service users and healthcare professionals<\/td><\/tr> |
| 49<\/td> | 43929_288<\/td> | Lucy Burr<\/td> | D1P2<\/td> | 05<\/td> | 02<\/td> | Management & Organization of clinical service<\/td> | Recognising Diffuse Panbronchiolitis in Multicultural Bronchiectasis Populations: The Diagnostic Value of Nasal Nitric Oxide<\/td><\/tr> |
| 50<\/td> | 43947_345<\/td> | Anthony De Soyza<\/td> | D1P2<\/td> | 05<\/td> | 03<\/td> | Management & Organization of clinical service<\/td> | UK Clinician Access, Utilisation and Eligibility Perspectives Genetic testing in Bronchiectasis: A National Survey<\/td><\/tr> |
| 51<\/td> | 43846_225<\/td> | Warnakulasuriya Susanne Nirodhani Fernando<\/td> | D1P2<\/td> | 05<\/td> | 04<\/td> | Management & Organization of clinical service<\/td> | Knowledge, Attitudes, and Practices Regarding Clinical Management of Bronchiectasis Among Doctors Managing Adult Respiratory Illnesses in Sri Lanka: A Cross-Sectional Study<\/td><\/tr> |
| 52<\/td> | 43699_93<\/td> | Nikolas Johl<\/td> | D1P2<\/td> | 05<\/td> | 05<\/td> | Management & Organization of clinical service<\/td> | Diagnostic Detectives: outcomes from the case files of a regional bronchiectasis diagnostic clinic<\/td><\/tr> |
| 53<\/td> | 43812_188<\/td> | Peter Kahn<\/td> | D1P2<\/td> | 05<\/td> | 06<\/td> | Management & Organization of clinical service<\/td> | Importance of Understanding the Patient Experience in Healthcare: An Example of the Integrated Patient Journey in Non-Cystic Fibrosis Bronchiectasis<\/td><\/tr> |
| 54<\/td> | 43814_189<\/td> | Peter A Kahn<\/td> | D1P2<\/td> | 05<\/td> | 07<\/td> | Management & Organization of clinical service<\/td> | Caregiver Perspectives on Pediatric Non-Cystic Fibrosis Bronchiectasis Clinical Trial Design: Insights from US Caregiver Panels<\/td><\/tr> |
| 55<\/td> | 43930_289<\/td> | Keating Rebecca<\/td> | D1P2<\/td> | 05<\/td> | 08<\/td> | Management & Organization of clinical service<\/td> | Improving access to airway clearance devices in bronchiectasis: A service evaluation of Aerobika provision through a Mater Foundation initiative<\/td><\/tr> |
| 56<\/td> | 43879_248<\/td> | Simone Tunesi<\/td> | D1P2<\/td> | 05<\/td> | 09<\/td> | Management & Organization of clinical service<\/td> | Unity is strength: early results from a joint pulmonology\u2013infectious diseases outpatient clinic for the management of infectious complications of bronchiectasis at the Alessandria University Hospital<\/td><\/tr> |
| 57<\/td> | 44140_485<\/td> | Sophia M\u00fcller<\/td> | D1P2<\/td> | 06<\/td> | 01<\/td> | NTM 1<\/td> | Molecular identification and resistance profile of respiratory NTM strains in a single center over a five-year period<\/td><\/tr> |
| 58<\/td> | 44092_448<\/td> | Rosa Andrade<\/td> | D1P2<\/td> | 06<\/td> | 02<\/td> | NTM 1<\/td> | Species Distribution and Geographic Clustering of Nontuberculous Mycobacterial Isolates at UC Irvine Medical Center, 2020\u20132024<\/td><\/tr> |
| 59<\/td> | 43493_66<\/td> | Chih Jung Chang<\/td> | D1P2<\/td> | 06<\/td> | 03<\/td> | NTM 1<\/td> | Drug Susceptibility Profiles of Clinically Relevant Nontuberculous Mycobacteria in Patients with Bronchiectasis: An Update from a Medical Center<\/td><\/tr> |
| 60<\/td> | 43749_124<\/td> | Hayoung Choi<\/td> | D1P2<\/td> | 06<\/td> | 04<\/td> | NTM 1<\/td> | Risk of mycobacterial lung disease in lung cancer survivors: A nationwide longitudinal study<\/td><\/tr> |
| 61<\/td> | 44021_413<\/td> | Paola Faverio<\/td> | D1P2<\/td> | 06<\/td> | 05<\/td> | NTM 1<\/td> | High Prevalence of Malnutrition and Sarcopenia in patients with NTM pulmonary disease in a High-Income Country<\/td><\/tr> |
| 62<\/td> | 44023_414<\/td> | Anas Hadeh<\/td> | D1P2<\/td> | 06<\/td> | 06<\/td> | NTM 1<\/td> | Solitary Pulmonary Nodules in Nontuberculous Mycobacterial Infection: An Underrecognized Presentation in Bronchoscopy Practice<\/td><\/tr> |
| 63<\/td> | 43809_186<\/td> | Eric Houpt<\/td> | D1P2<\/td> | 06<\/td> | 07<\/td> | NTM 1<\/td> | Clinical outcomes in a prospective cohort of 105 adults with speciated Mycobacterium avium complex lung disease, 2021-2026<\/td><\/tr> |
| 64<\/td> | 43926_286<\/td> | Hyung-Jun Kim<\/td> | D1P2<\/td> | 06<\/td> | 08<\/td> | NTM 1<\/td> | Pulmonary Rehabilitation in Nontuberculous Mycobacterial Pulmonary Disease: A Prospective Cohort Study<\/td><\/tr> |
| 65<\/td> | 43781_162<\/td> | NITYANAND JAIN<\/td> | D1P2<\/td> | 06<\/td> | 09<\/td> | NTM 1<\/td> | Operational Constraints Shape Real-World Weighting of NTM-PD Diagnostic Domains in Clinical Decision-Making<\/td><\/tr> |
| 66<\/td> | 43889_256<\/td> | Meg Crisafulli<\/td> | D1P2<\/td> | 07<\/td> | 01<\/td> | Allied Healthcare & Patients<\/td> | Identifying international research priorities for bronchiectasis<\/td><\/tr> |
| 67<\/td> | 43834_207<\/td> | Anthony De Soyza<\/td> | D1P2<\/td> | 07<\/td> | 02<\/td> | Allied Healthcare & Patients<\/td> | Learning Points from Patient Experiences of Video-Supported Recruitment: A SWAT within the BOAT Trial<\/td><\/tr> |
| 68<\/td> | 43855_227<\/td> | Linda Esposito<\/td> | D1P2<\/td> | 07<\/td> | 03<\/td> | Allied Healthcare & Patients<\/td> | Early Real-World Experience with Brinsupri\u2020 on Airway Clearance and Clinical Symptoms in Bronchiectasis<\/td><\/tr> |
| 69<\/td> | 43925_285<\/td> | Rebecca Keating<\/td> | D1P2<\/td> | 07<\/td> | 04<\/td> | Allied Healthcare & Patients<\/td> | Redefining Bronchiectasis Care: What Patients Experience in a CF-Inspired Multidisciplinary Clinic<\/td><\/tr> |
| 70<\/td> | 43862_234<\/td> | Annemarie Lee<\/td> | D1P2<\/td> | 07<\/td> | 05<\/td> | Allied Healthcare & Patients<\/td> | Prevalence, clinical effects and treatment options for urinary incontinence in people with bronchiectasis: a systematic review<\/td><\/tr> |
| 71<\/td> | 43861_233<\/td> | Annemarie Lee<\/td> | D1P2<\/td> | 07<\/td> | 06<\/td> | Allied Healthcare & Patients<\/td> | Telehealth healthcare delivery in adults with bronchiectasis: a systematic review<\/td><\/tr> |
| 72<\/td> | 43863_235<\/td> | Annemarie Lee<\/td> | D1P2<\/td> | 07<\/td> | 07<\/td> | Allied Healthcare & Patients<\/td> | Telehealth physiotherapy for adults with bronchiectasis: a controlled trial<\/td><\/tr> |
| 73<\/td> | 43783_164<\/td> | Jordan Louie<\/td> | D1P2<\/td> | 07<\/td> | 08<\/td> | Allied Healthcare & Patients<\/td> | Pediatric to adult transition pathway in a PCD Clinic: impacts on patients and their families<\/td><\/tr> |
| 74<\/td> | 43821_196<\/td> | Judy Schloss<\/td> | D1P2<\/td> | 07<\/td> | 09<\/td> | Allied Healthcare & Patients<\/td> | Real-World Airway Clearance Practices in Bronchiectasis- A Patient Reported Survey<\/td><\/tr> |
| 75<\/td> | 43786_166<\/td> | Emily Ward<\/td> | D1P2<\/td> | 07<\/td> | 10<\/td> | Allied Healthcare & Patients<\/td> | Living Life with Bronchiectasis: A patient experience survey from the LiveBE study<\/td><\/tr> |
| 76<\/td> | 43827_200<\/td> | Shapaguli Aizezi<\/td> | D1P3<\/td> | 08<\/td> | 01<\/td> | PCD and Paediatrics 1<\/td> | Diffuse Bronchiolitis as a Respiratory Phenotype in Chinese Children with Primary Ciliary Dyskinesia: A Clinical and Genetic Study<\/td><\/tr> |
| 77<\/td> | 43829_202<\/td> | Shapaguli Aizezi<\/td> | D1P3<\/td> | 08<\/td> | 02<\/td> | PCD and Paediatrics 1<\/td> | Evaluation of Screening Tools and Early Diagnostic Predictors for Primary Ciliary Dyskinesia in Chinese Children<\/td><\/tr> |
| 78<\/td> | 44078_437<\/td> | Doha BENCHAJI<\/td> | D1P3<\/td> | 08<\/td> | 03<\/td> | PCD and Paediatrics 1<\/td> | Clinical and Etiological Profile of Bronchiectasis in Morocco<\/td><\/tr> |
| 79<\/td> | 44074_433<\/td> | Doha Benchaji<\/td> | D1P3<\/td> | 08<\/td> | 04<\/td> | PCD and Paediatrics 1<\/td> | From underdiagnosis to genetic confirmation: unveiling Primary Ciliary Dyskinesia in Morocco<\/td><\/tr> |
| 80<\/td> | 43987_346<\/td> | Crystal Bourke<\/td> | D1P3<\/td> | 08<\/td> | 05<\/td> | PCD and Paediatrics 1<\/td> | Longitudinal lung clearance index measurements in children and adolescents with bronchiectasis<\/td><\/tr> |
| 81<\/td> | 44214_506<\/td> | Jessica Melfis Cemlyn-Jones<\/td> | D1P3<\/td> | 08<\/td> | 06<\/td> | PCD and Paediatrics 1<\/td> | One Mutation, Three Lives: Variable Expression of Primary Ciliary Dyskinesia Type 7 in Siblings<\/td><\/tr> |
| 82<\/td> | 43870_241<\/td> | Raphael Ewen<\/td> | D1P3<\/td> | 08<\/td> | 07<\/td> | PCD and Paediatrics 1<\/td> | Dupilumab for chronic rhinosinusitis with nasal polyps in adults with primary ciliary dyskinesia: a case series<\/td><\/tr> |
| 83<\/td> | 43912_275<\/td> | Moshe Heching<\/td> | D1P3<\/td> | 08<\/td> | 08<\/td> | PCD and Paediatrics 1<\/td> | Recombinant Human DNase in Primary Ciliary Dyskinesia: A Multi-Center Randomized Controlled Trial Protocol<\/td><\/tr> |
| 84<\/td> | 43748_123<\/td> | Nena Karavasiloglou<\/td> | D1P3<\/td> | 08<\/td> | 09<\/td> | PCD and Paediatrics 1<\/td> | A systematic review of growth-related parameters and nutritional status of patients with primary ciliary dyskinesia (PCD)<\/td><\/tr> |
| 85<\/td> | 43793_173<\/td> | Nena Karavasiloglou<\/td> | D1P3<\/td> | 08<\/td> | 10<\/td> | PCD and Paediatrics 2<\/td> | Nutritional supplement use among people with primary ciliary dyskinesia<\/td><\/tr> |
| 86<\/td> | 43791_171<\/td> | Anna-Lena Katzke<\/td> | D1P3<\/td> | 08<\/td> | 11<\/td> | PCD and Paediatrics 2<\/td> | Automatic reanalysis of genetic data from patients with Primary Ciliary Dyskinesia<\/td><\/tr> |
| 87<\/td> | 43794_174<\/td> | Eleni Kortianou<\/td> | D1P3<\/td> | 08<\/td> | 12<\/td> | PCD and Paediatrics 2<\/td> | Cardiorespiratory responses during the modified Shuttle walk test in children with chronic suppurative lung diseases. Comparisons with healthy, age-matched peers.<\/td><\/tr> |
| 88<\/td> | 43796_176<\/td> | Eleni Kortianou<\/td> | D1P3<\/td> | 08<\/td> | 13<\/td> | PCD and Paediatrics 2<\/td> | User satisfaction and co-designing a website for physiotherapy management for children with chronic suppurative lung diseases<\/td><\/tr> |
| 89<\/td> | 43767_141<\/td> | Panagiotis Dalamarinis<\/td> | D1P3<\/td> | 08<\/td> | 14<\/td> | PCD and Paediatrics 2<\/td> | Using 6-Minute Walk Test and Chester Step Test for Detecting Exertional Desaturation in Children with Chronic Suppurative Lung Disease: A Pilot Study.<\/td><\/tr> |
| 90<\/td> | 43906_269<\/td> | MINJUN LIAO<\/td> | D1P3<\/td> | 08<\/td> | 15<\/td> | PCD and Paediatrics 2<\/td> | Diagnostic Pitfall in High-Speed Video Analysis of Primary Ciliary Dyskinesia: A TTC12-Related Case with Mixed Ciliary Activity<\/td><\/tr> |
| 91<\/td> | 43905_268<\/td> | Ying Liu<\/td> | D1P3<\/td> | 08<\/td> | 16<\/td> | PCD and Paediatrics 2<\/td> | AK8 deficiency causes primary ciliary dyskinesia with normal ciliary ultrastructure in humans and mice<\/td><\/tr> |
| 92<\/td> | 43756_131<\/td> | Regina Monteiro<\/td> | D1P3<\/td> | 08<\/td> | 17<\/td> | PCD and Paediatrics 2<\/td> | Diagnostic Overlap Between PCD and CFTR Dysfunction: An Unresolved Case with Discordant Findings<\/td><\/tr> |
| 93<\/td> | 43514_74<\/td> | Ahmad Mohammad Alessa<\/td> | D1P3<\/td> | 09<\/td> | 01<\/td> | Treatments<\/td> | CASE REPORT: OPTIMIZING POSITIVE END-EXPIRATORY PRESSURE USING ESOPHAGEAL BALLOON CATHETER MONITORING IN ARDS<\/td><\/tr> |
| 94<\/td> | 43191_34<\/td> | Ezequiel Baran<\/td> | D1P3<\/td> | 09<\/td> | 02<\/td> | Treatments<\/td> | Real-World Outcomes of Nebulized Levofloxacin in Chronic Bronchial Infection and Non-Cystic Fibrosis Bronchiectasis: A Comparative Analysis from the INBREATHING Registry<\/td><\/tr> |
| 95<\/td> | 43625_83<\/td> | Robert Flowers<\/td> | D1P3<\/td> | 09<\/td> | 03<\/td> | Treatments<\/td> | Early Real-World Experience With Brensocatib in a Safety-Net Bronchiectasis Cohort<\/td><\/tr> |
| 96<\/td> | 43883_252<\/td> | Jiahui Han<\/td> | D1P3<\/td> | 09<\/td> | 04<\/td> | Treatments<\/td> | Multi-Target Mechanisms of Kale as a Dietary Intervention in Bronchiectasis: A Network Pharmacology and Molecular Simulation Study<\/td><\/tr> |
| 97<\/td> | 43806_183<\/td> | Jin Hwa Lee<\/td> | D1P3<\/td> | 09<\/td> | 05<\/td> | Treatments<\/td> | Impact of inhaled corticosteroids on survival in patients with bronchiectasis<\/td><\/tr> |
| 98<\/td> | 44093_449<\/td> | Andrade Rosa<\/td> | D1P3<\/td> | 09<\/td> | 06<\/td> | Treatments<\/td> | Incidence, Timing, and Risk Factors for Hepatotoxicity During First-Line Anti-Tuberculosis Therapy in a Multi-Health-System Real-World Cohort<\/td><\/tr> |
| 99<\/td> | 43816_191<\/td> | Judy Schloss<\/td> | D1P3<\/td> | 09<\/td> | 07<\/td> | Treatments<\/td> | Inhaled Tranexamic Acid Dosing and Environmental Medication Loss From Three Jet Nebulizer Configurations<\/td><\/tr> |
| 100<\/td> | 43246_36<\/td> | MINH DAO NGO<\/td> | D2P1<\/td> | 02<\/td> | 14<\/td> | BASIC SCIENCE 2<\/td> | Bronchoalveolar oxysterols are associated with disease severity and lung function decline in bronchiectasis<\/td><\/tr> |
| 101<\/td> | 43724_105<\/td> | Leonid Ramov<\/td> | D2P1<\/td> | 02<\/td> | 15<\/td> | BASIC SCIENCE 2<\/td> | An incidental finding of infected bronchiectasis in a patient with an Asthma COPD overlap exacerbation a 10-year follow up.<\/td><\/tr> |
| 102<\/td> | 43857_229<\/td> | Leonid Ramov<\/td> | D2P1<\/td> | 02<\/td> | 16<\/td> | BASIC SCIENCE 2<\/td> | Rapidly Progressive Cystic Bronchiectasis in Suspected Primary Ciliary Dyskinesia: A Challenging Case with Recurrent Severe Exacerbations (Case Report)<\/td><\/tr> |
| 103<\/td> | 43805_182<\/td> | Ilona Rosenboom<\/td> | D2P1<\/td> | 02<\/td> | 17<\/td> | BASIC SCIENCE 2<\/td> | Linking sputum metagenome composition to inflammatory profiles in bronchiectasis: a pilot study<\/td><\/tr> |
| 104<\/td> | 43517_75<\/td> | Elena Schneider-Futschik<\/td> | D2P1<\/td> | 02<\/td> | 18<\/td> | BASIC SCIENCE 2<\/td> | Defining the Role of Dipeptidyl Peptidase-1 in Murine Lung Immune Regulation<\/td><\/tr> |
| 105<\/td> | 43792_172<\/td> | Siobhan Singh<\/td> | D2P1<\/td> | 02<\/td> | 19<\/td> | BASIC SCIENCE 2<\/td> | To challenge or not to challenge? What can we learn from nebulised drug reaction assessment data in non-cystic fibrosis bronchiectasis? A retrospective study.<\/td><\/tr> |
| 106<\/td> | 43747_122<\/td> | Ruth Tal-Singer<\/td> | D2P1<\/td> | 02<\/td> | 20<\/td> | BASIC SCIENCE 2<\/td> | Global Baseline Knowledge of Bronchiectasis: Results from the GAAPP Multilingual Online Interactive Quiz<\/td><\/tr> |
| 107<\/td> | 43651_89<\/td> | Aman Tiwari<\/td> | D2P1<\/td> | 02<\/td> | 21<\/td> | BASIC SCIENCE 2<\/td> | Cigarette smoke extract and LPS trigger RIPK1\/RIPK3\/MLKL-mediated necroptosis and fibrotic lung injury<\/td><\/tr> |
| 108<\/td> | 43642_85<\/td> | Pauline Vermoesen<\/td> | D2P1<\/td> | 02<\/td> | 22<\/td> | BASIC SCIENCE 2<\/td> | AIR-BREES: Airway Inhalation Risks\u2014a Bronchiectasis Respiratory Environmental Exposure Survey<\/td><\/tr> |
| 109<\/td> | 43762_137<\/td> | Christine K. Wong<\/td> | D2P1<\/td> | 02<\/td> | 23<\/td> | BASIC SCIENCE 2<\/td> | Pseudomonas aeruginosa infection increases sputum viscoelasticity and chronic inflammation in bronchiectasis<\/td><\/tr> |
| 110<\/td> | 44059_419<\/td> | Yingzhou Xie<\/td> | D2P1<\/td> | 02<\/td> | 24<\/td> | BASIC SCIENCE 2<\/td> | The response regulator-encoding PA1437 controls antibiotic persistence in Pseudomonas aeruginosa and contributes to recalcitrant chronic infection in bronchiectasis<\/td><\/tr> |
| 111<\/td> | 43885_253<\/td> | B. Shoshana Zha<\/td> | D2P1<\/td> | 02<\/td> | 25<\/td> | BASIC SCIENCE 2<\/td> | CFTR Function, Modulator Access, and Host-Pathogen Transcriptomics of M. avium in Bronchiectasis and NTM Lung Disease<\/td><\/tr> |
| 112<\/td> | 43713_97<\/td> | Ilgar Mustafayev<\/td> | D2P1<\/td> | 03<\/td> | 15<\/td> | REGISTRIES & TRAILS 2<\/td> | Evaluation of Surfactant Therapy in the Treatment of Bronchiectasis<\/td><\/tr> |
| 113<\/td> | 43839_215<\/td> | Lidia Perea<\/td> | D2P1<\/td> | 03<\/td> | 16<\/td> | REGISTRIES & TRAILS 2<\/td> | The frequent exacerbator phenotype in bronchiectasis revisited: Data from the EMBARC registry<\/td><\/tr> |
| 114<\/td> | 43776_150<\/td> | Michal Shteinberg<\/td> | D2P1<\/td> | 03<\/td> | 17<\/td> | REGISTRIES & TRAILS 2<\/td> | Final pooled data from Phase II studies (AIRLEAF\u00ae, CLAIRLEAF\u00ae) of the dipeptidyl peptidase 1 (or Cathepsin C) inhibitor verducatib in bronchiectasis<\/td><\/tr> |
| 115<\/td> | 44026_416<\/td> | Colin Swenson<\/td> | D2P1<\/td> | 03<\/td> | 18<\/td> | REGISTRIES & TRAILS 2<\/td> | Comparison of Aerobika versus other PEP therapies, in addition to inhaled hypertonic saline, among adult patients in the U.S. Bronchiectasis Research Registry<\/td><\/tr> |
| 116<\/td> | 43864_236<\/td> | Ruth Tal-Singer<\/td> | D2P1<\/td> | 03<\/td> | 19<\/td> | REGISTRIES & TRAILS 2<\/td> | First International Multicenter Validation of the Chronic Airways Assessment Test (CAAT)\u2122 in Bronchiectasis<\/td><\/tr> |
| 117<\/td> | 43869_240<\/td> | Stephanie Thee<\/td> | D2P1<\/td> | 03<\/td> | 20<\/td> | REGISTRIES & TRAILS 2<\/td> | Nocturnal digital cough monitoring in people with Primary Ciliary Dyskinesia and Cystic Fibrosis \u2013 First results of an international multi-centre observational study<\/td><\/tr> |
| 118<\/td> | 43881_250<\/td> | Christina Thornton<\/td> | D2P1<\/td> | 03<\/td> | 21<\/td> | REGISTRIES & TRAILS 2<\/td> | The Impact of Proton Pump Inhibitor (PPI) Use on Exacerbation Rates in Patients with Bronchiectasis: An Analysis of the US Bronchiectasis and NTM Research Registry<\/td><\/tr> |
| 119<\/td> | 43365_39<\/td> | Kazuya Tone<\/td> | D2P1<\/td> | 03<\/td> | 22<\/td> | REGISTRIES & TRAILS 2<\/td> | Induced sputum collection using Lung Flute\u00ae ECO in suspected NTM pulmonary disease with bronchiectatic features: a prospective interim analysis<\/td><\/tr> |
| 120<\/td> | 43788_168<\/td> | Claire Wainwright<\/td> | D2P1<\/td> | 03<\/td> | 23<\/td> | REGISTRIES & TRAILS 2<\/td> | Finding the Optimal Regimen for Mycobacterium abscessus Treatment (FORMaT) Trial: First Interim Analysis of 61 Intervention Participants after Short Intensive Therapy<\/td><\/tr> |
| 121<\/td> | 43866_238<\/td> | Meret Moormann<\/td> | D2P1<\/td> | 04<\/td> | 09<\/td> | Comorbidities, Immunology & Inflammation 2<\/td> | Serum Club Cell Protein 16 (CC16) and its Association with Bronchiectasis Severity and Activity \u2013 Data from the German Bronchiectasis Registry PROGNOSIS<\/td><\/tr> |
| 122<\/td> | 43927_287<\/td> | Craig Schofield<\/td> | D2P1<\/td> | 04<\/td> | 10<\/td> | Comorbidities, Immunology & Inflammation 2<\/td> | Single-cell RNA sequencing of induced sputum to characterise airway immune cells in paediatric bronchiectasis<\/td><\/tr> |
| 123<\/td> | 43777_158<\/td> | Michal Shteinberg<\/td> | D2P1<\/td> | 04<\/td> | 11<\/td> | Comorbidities, Immunology & Inflammation 2<\/td> | Efficacy and Safety of Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis and Comorbid Chronic Rhinosinusitis: A Subgroup Analysis of the ASPEN Trial<\/td><\/tr> |
| 124<\/td> | 43778_159<\/td> | Colin Swenson<\/td> | D2P1<\/td> | 04<\/td> | 12<\/td> | Comorbidities, Immunology & Inflammation 2<\/td> | Efficacy and Safety of Brensocatib in Patients With Non-cystic Fibrosis Bronchiectasis (NCFB) by ROSE Criteria: A Post Hoc Analysis of the ASPEN Trial<\/td><\/tr> |
| 125<\/td> | 43725_106<\/td> | Lynn Te Slaa<\/td> | D2P1<\/td> | 04<\/td> | 13<\/td> | Comorbidities, Immunology & Inflammation 2<\/td> | Bronchiectasis as an underrecognized extra-intestinal manifestation of inflammatory bowel disease<\/td><\/tr> |
| 126<\/td> | 44020_412<\/td> | Rabindra Tirouvanziam<\/td> | D2P1<\/td> | 04<\/td> | 14<\/td> | Comorbidities, Immunology & Inflammation 2<\/td> | Sputum metabolomics reveals a shared oxidant signature in non-CF and CF bronchiectasis<\/td><\/tr> |
| 127<\/td> | 43988_380<\/td> | Harm Tiddens<\/td> | D2P1<\/td> | 04<\/td> | 15<\/td> | Comorbidities, Immunology & Inflammation 2<\/td> | Bronchiectasis Without Dilatation? How Emphysema Confounds CT Diagnosis<\/td><\/tr> |
| 128<\/td> | 43764_139<\/td> | Aditi Loewe<\/td> | D2P1<\/td> | 05<\/td> | 13<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Novel Polymeric Reducing Agents as Mucus Modulators in Cystic Fibrosis<\/td><\/tr> |
| 129<\/td> | 43842_217<\/td> | Gabriele Matschiner<\/td> | D2P1<\/td> | 05<\/td> | 14<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | ATL-105, a novel multimodal serine protease inhibitor with immunomodulatory and anti-infective properties for the treatment of non-CF bronchiectasis<\/td><\/tr> |
| 130<\/td> | 43545_76<\/td> | Jia hui He<\/td> | D2P1<\/td> | 05<\/td> | 15<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Multidimensional Assessment of the Clinical Evolution of Asthma-Bronchiectasis Overlap<\/td><\/tr> |
| 131<\/td> | 43195_35<\/td> | Jakob Raith<\/td> | D2P1<\/td> | 05<\/td> | 16<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Clinical implications of traction bronchiectasis in IPF and fibrotic RA-ILD \u2013 A retrospective single-center cohort study<\/td><\/tr> |
| 132<\/td> | 43896_262<\/td> | Virginia Santello<\/td> | D2P1<\/td> | 05<\/td> | 17<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Oscillometry in the assessment of disease activity and severity in bronchiectasis<\/td><\/tr> |
| 133<\/td> | 43396_49<\/td> | Hisham Saumtally<\/td> | D2P1<\/td> | 05<\/td> | 18<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | The LTAP-Treated Bronchiectasis Phenotype: Severity, Exacerbation Burden and Microbiological Risk in a Large Tertiary Centre Cohort<\/td><\/tr> |
| 134<\/td> | 43715_99<\/td> | Constance Takawira<\/td> | D2P1<\/td> | 05<\/td> | 19<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Patient-focused Target Product Profiles for the development of phage therapies to treat lung infections in cystic fibrosis<\/td><\/tr> |
| 135<\/td> | 43817_192<\/td> | Ruth Tal-Singer<\/td> | D2P1<\/td> | 05<\/td> | 20<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Patient engagement and collaboration in the design of the Phase III AIRTIVITY\u00ae study in people living with bronchiectasis<\/td><\/tr> |
| 136<\/td> | 43807_184<\/td> | Laura Tasca<\/td> | D2P1<\/td> | 05<\/td> | 21<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Compartmentalized PDE3\/4 Modulation by Inhaled KIT2014 Improves Airway Epithelial Function and Limits Inflammation in in Non-Cystic Fibrosis Bronchiectasis-relevant models<\/td><\/tr> |
| 137<\/td> | 43761_136<\/td> | Wen-Wen Wang<\/td> | D2P1<\/td> | 05<\/td> | 22<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | A Mismatch Between Physiology and Treatment in Bronchiectasis with Airflow Obstruction\u2014Data from BE-China<\/td><\/tr> |
| 138<\/td> | 43922_282<\/td> | Shoshana Zha<\/td> | D2P1<\/td> | 05<\/td> | 23<\/td> | Cystic Fibrosis and Bronchiectasis 2<\/td> | Characterizing CFTR-Related Disorder Bronchiectasis and Response to Modulator Therapy: A Prospective Multicenter Registry Cohort<\/td><\/tr> |
| 139<\/td> | 43872_243<\/td> | Ahmad Mohammad Alessa<\/td> | D2P2<\/td> | 06<\/td> | 01<\/td> | Infections<\/td> | Refractory Pediatric ARDS Due to Tuberculosis Managed with V-V ECMO: Case Report<\/td><\/tr> |
| 140<\/td> | 43765_140<\/td> | Fengming Ding<\/td> | D2P2<\/td> | 06<\/td> | 02<\/td> | Infections<\/td> | Association of inhaled corticosteroid use and acquiring Pseudomonas aeruginosa in eosinophilic bronchiectasis patients<\/td><\/tr> |
| 141<\/td> | 43854_226<\/td> | Warnakulasuriya Susanne Nirodhani Fernando<\/td> | D2P2<\/td> | 06<\/td> | 03<\/td> | Infections<\/td> | Bacteriological Profile of Sputum Pyogenic Cultures, Associated Comorbidities, and Complications in Patients with Bronchiectasis Admitted to a Tertiary Care Respiratory Unit in Sri Lanka: A Descriptive Case Series- Preliminary report<\/td><\/tr> |
| 142<\/td> | 43760_135<\/td> | Freddy Frost<\/td> | D2P2<\/td> | 06<\/td> | 04<\/td> | Infections<\/td> | 50 shades of green: Longitudinal dynamics of sputum colour and associated clinical outcomes in bronchiectasis<\/td><\/tr> |
| 143<\/td> | 43763_138<\/td> | Espen E Groth<\/td> | D2P2<\/td> | 06<\/td> | 05<\/td> | Infections<\/td> | Intra-host Pseudomonas aeruginosa dynamics under antibiotic pressure in COPD and non-CF bronchiectasis: results from an observational trial.<\/td><\/tr> |
| 144<\/td> | 43795_175<\/td> | Moshe Heching<\/td> | D2P2<\/td> | 06<\/td> | 06<\/td> | Infections<\/td> | Taking a shot at the future: Impact of vaccination compliance on exacerbations in bronchiectasis patients<\/td><\/tr> |
| 145<\/td> | 44084_442<\/td> | De Sanctis Jorgelina<\/td> | D2P2<\/td> | 06<\/td> | 07<\/td> | Infections<\/td> | Evolving Multidrug-Resistant Pseudomonas aeruginosa and Nontuberculous Mycobacterial Infections in Cystic Fibrosis Bronchiectasis Through Bilateral Lung Transplantation<\/td><\/tr> |
| 146<\/td> | 44068_427<\/td> | Nguyen-Ho Lam<\/td> | D2P2<\/td> | 06<\/td> | 08<\/td> | Infections<\/td> | Etiological and Microbiological Phenotypes of Non-Cystic Fibrosis Bronchiectasis in Vietnam: A High Tuberculosis-Burden Cohort<\/td><\/tr> |
| 147<\/td> | 43757_132<\/td> | Yue Su<\/td> | D2P2<\/td> | 06<\/td> | 09<\/td> | Infections<\/td> | AI-Based Risk Prediction of Pseudomonas aeruginosa and NTM Infections in Bronchiectasis Patients Using Chest CT Imaging<\/td><\/tr> |
| 148<\/td> | 43856_228<\/td> | Georg Vrana<\/td> | D2P2<\/td> | 06<\/td> | 10<\/td> | Infections<\/td> | Treatment Outcomes in Chronic Pulmonary Aspergillosis: A Single-Center Retrospective Analysis<\/td><\/tr> |
| 149<\/td> | 43815_190<\/td> | Zhongbo Chen<\/td> | D2P2<\/td> | 07<\/td> | 10<\/td> | NTM 2<\/td> | The Immune\u2013Metabolic\u2013Pathogen Interaction Network of PD-1\u207a T Cell Glycolytic Reprogramming and LAM\/Extracellular Vesicles in Non-tuberculous Mycobacterial Pulmonary Disease<\/td><\/tr> |
| 150<\/td> | 43894_261<\/td> | P. Makani<\/td> | D2P2<\/td> | 07<\/td> | 11<\/td> | NTM 2<\/td> | Quantification of structural lung abnormalities in a cohort bronchiectasis patients with and without Nontuberculous Mycobacteria using the manual BEST-NTM score<\/td><\/tr> |
| 151<\/td> | 44060_420<\/td> | Carla McWilliams<\/td> | D2P2<\/td> | 07<\/td> | 12<\/td> | NTM 2<\/td> | Nontuberculous Mycobacteria Commonly Detected in Bronchoscopy Patients Without Prior Clinical Suspicion in an Endemic Region<\/td><\/tr> |
| 152<\/td> | 43389_44<\/td> | Hisham Saumtally<\/td> | D2P2<\/td> | 07<\/td> | 13<\/td> | NTM 2<\/td> | Identifying Vulnerable Patients in NTM PD: Respiratory Comorbidity and Treatment Intolerance Drive Mortality Risk<\/td><\/tr> |
| 153<\/td> | 43359_38<\/td> | Johnny Che I Su<\/td> | D2P2<\/td> | 07<\/td> | 14<\/td> | NTM 2<\/td> | CHARACTERISATION OF ADULT PATIENTS WITH BRONCHIECTASIS AND SPINAL DEFORMITIES<\/td><\/tr> |
| 154<\/td> | 44085_443<\/td> | Harm Tiddens<\/td> | D2P2<\/td> | 07<\/td> | 15<\/td> | NTM 2<\/td> | Automatic Mucus Plug Quantification in Bronchiectasis Patients with NTM Infection<\/td><\/tr> |
| 155<\/td> | 43878_247<\/td> | Simone Tunesi<\/td> | D2P2<\/td> | 07<\/td> | 16<\/td> | NTM 2<\/td> | Epidemiology and Spatial Distribution of Non-Tuberculous Mycobacteria in a North Italian Region<\/td><\/tr> |
| 156<\/td> | 43877_246<\/td> | Simone Tunesi<\/td> | D2P2<\/td> | 07<\/td> | 17<\/td> | NTM 2<\/td> | When a diagnosis doesn\u2019t follow the script: a case report of a M. abscessus pulmonary disease mimicking a rare condition in a bronchiectasic patient<\/td><\/tr> |
| 157<\/td> | 43397_50<\/td> | Sigrid van Brummelen<\/td> | D2P2<\/td> | 07<\/td> | 18<\/td> | NTM 2<\/td> | NTM mapping in the Rotterdam region in the Netherlands<\/td><\/tr> |
| 158<\/td> | 43797_177<\/td> | Cara Varley<\/td> | D2P2<\/td> | 07<\/td> | 19<\/td> | NTM 2<\/td> | Changes in Complete Blood Count During 12 Months of Treatment for Mycobacterium avium complex Pulmonary Disease: A MAC 2v3 analysis<\/td><\/tr> |
| 159<\/td> | 44063_423<\/td> | James O'Hanlon<\/td> | D2P2<\/td> | 08<\/td> | 18<\/td> | PCD and Paediatrics 3<\/td> | A family with primary ciliary dyskinesia (PCD) from pathogenic variants in HYDIN \u2013 a case series<\/td><\/tr> |
| 160<\/td> | 43934_304<\/td> | Charlotte O. Pioch<\/td> | D2P2<\/td> | 08<\/td> | 19<\/td> | PCD and Paediatrics 3<\/td> | Comparison of cut-off values for nasal nitric oxide measurements in children under four years of age<\/td><\/tr> |
| 161<\/td> | 44086_444<\/td> | Robert Reklow<\/td> | D2P2<\/td> | 08<\/td> | 20<\/td> | PCD and Paediatrics 3<\/td> | An Optimized Immunofluorescence Panel Improves Diagnostic Accuracy for Primary Ciliary Dyskinesia<\/td><\/tr> |
| 162<\/td> | 44073_432<\/td> | Amelia Shoemark<\/td> | D2P2<\/td> | 08<\/td> | 21<\/td> | PCD and Paediatrics 3<\/td> | Characteristics and outcomes of adults with bronchiectasis due to primary ciliary dyskinesia: combined analysis of EMBARC, Australia, USA and Canadian bronchiectasis registries<\/td><\/tr> |
| 163<\/td> | 43913_276<\/td> | Ben O. Staar<\/td> | D2P2<\/td> | 08<\/td> | 22<\/td> | PCD and Paediatrics 3<\/td> | Integrated Structural, Functional, and Clinical Characterization of NME5 in Primary Ciliary Dyskinesia<\/td><\/tr> |
| 164<\/td> | 44208_503<\/td> | Lea Terbeck<\/td> | D2P2<\/td> | 08<\/td> | 23<\/td> | PCD and Paediatrics 3<\/td> | Establishing Scanning Electron Microscopy for air-liquid interface cultures of individuals with ciliopathies<\/td><\/tr> |
| 165<\/td> | 43770_144<\/td> | Tanya Theriault<\/td> | D2P2<\/td> | 08<\/td> | 24<\/td> | PCD and Paediatrics 3<\/td> | Implementation of emotional wellness questionnaires in primary ciliary dyskinesia clinic: A social work led quality improvement project<\/td><\/tr> |
| 166<\/td> | 43916_278<\/td> | D\u00f6rthe Th\u00fc\u00df<\/td> | D2P2<\/td> | 08<\/td> | 25<\/td> | PCD and Paediatrics 3<\/td> | AK8 deficiency causes primary ciliary dyskinesia by disrupting energy homeostasis in the airways<\/td><\/tr> |
| 167<\/td> | 43800_179<\/td> | Dan-hui Yang<\/td> | D2P2<\/td> | 08<\/td> | 26<\/td> | PCD and Paediatrics 3<\/td> | In Vitro Gene Therapy Study of Primary Ciliary Dyskinesia Based on DNAI1-mRNA Lipid Nanoparticles<\/td><\/tr> |
| 168<\/td> | 43513_73<\/td> | Ahmad Mohammad Alessa<\/td> | D2P3<\/td> | 01<\/td> | 01<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | The Impact Of Prone Positioning As A Respiratory Therapy Protocol In ICU Patients, Scoping Review<\/td><\/tr> |
| 169<\/td> | 44194_494<\/td> | Martina Santambrogio<\/td> | D2P3<\/td> | 01<\/td> | 02<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Feasibility and Clinical Utility of Forced Oscillation Technique (FOT) as an Outcome Measure for Airway Clearance Efficacy in Non-Cystic Fibrosis Bronchiectasis: A Pilot Study<\/td><\/tr> |
| 170<\/td> | 43917_279<\/td> | Beatriz Herrero-Cortina<\/td> | D2P3<\/td> | 01<\/td> | 03<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Inflammation, Cardiac Autonomic Function, and Exercise Capacity in Bronchiectasis: Exploring Interrelated Mechanisms<\/td><\/tr> |
| 171<\/td> | 44025_415<\/td> | Rhiannon Jones<\/td> | D2P3<\/td> | 01<\/td> | 04<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Physiotherapy Support Staff in Airway Clearance: A Competency\u2011Led Approach<\/td><\/tr> |
| 172<\/td> | 43774_148<\/td> | Eleni Kortianou<\/td> | D2P3<\/td> | 01<\/td> | 05<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Association Between Airway Clearance Technique Adherence and Exacerbation Risk in Children and Adolescents With Non-Cystic Fibrosis Bronchiectasis: A Retrospective Cohort Study<\/td><\/tr> |
| 173<\/td> | 43758_133<\/td> | Yang Liu<\/td> | D2P3<\/td> | 01<\/td> | 06<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Airway clearance management for bronchiectasis in China: a multicentre cross-sectional study from the Chinese Bronchiectasis Registry (BE-China)<\/td><\/tr> |
| 174<\/td> | 44141_487<\/td> | Bei Mao<\/td> | D2P3<\/td> | 01<\/td> | 07<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis with exacerbation: a multicenter randomized controlled clinical trial<\/td><\/tr> |
| 175<\/td> | 43495_67<\/td> | Helper Nir<\/td> | D2P3<\/td> | 01<\/td> | 08<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Mechanical insufflator exsufflation as means for airway clearance in children with non CF- bronchiectasis \u2013 a case report<\/td><\/tr> |
| 176<\/td> | 43440_59<\/td> | Erick Ouma<\/td> | D2P3<\/td> | 01<\/td> | 09<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Effectiveness of mucolytic-assisted respiratory physiotherapy in optimizing airway clearance among patients with chronic bronchiectasis: A case report in Nairobi, Kenya.<\/td><\/tr> |
| 177<\/td> | 43819_194<\/td> | MERTSCH Pontus<\/td> | D2P3<\/td> | 01<\/td> | 10<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Real\u2011World evidence of Simeox airway clearance device in Muco\u2011Obstructive Lung Diseases: Results of the German Prospective Multicenter IMPROVE Study<\/td><\/tr> |
| 178<\/td> | 44206_502<\/td> | Martina Santambrogio<\/td> | D2P3<\/td> | 01<\/td> | 11<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | Pelvic Floor Dysfunctions in Non-CF Bronchiectasis: A Pilot Study<\/td><\/tr> |
| 179<\/td> | 43824_197<\/td> | Svenja Strassburg<\/td> | D2P3<\/td> | 01<\/td> | 12<\/td> | Respiratory Physiotherapy and Airway Clearance<\/td> | An Investigation into Different Oscillating Positive Expiratory Pressure (OPEP) Devices, Assessing Laboratory Metrics Relevant to Performance<\/td><\/tr><\/table><\/div>\r\n\r\n\r\n |